Revenue and Profit Increase
Eisai achieved an increase in revenue and operating profit for the third quarter of fiscal year 2023, with revenue at JPY 551.3 billion, marking a 1% increase from the previous year.
Growth in Pharmaceutical Business
Sales of Lenvima increased by JPY 31.9 billion (up 17%) and Dayvigo increased by JPY 9.2 billion (up 42%) year-on-year.
LEQEMBI Market Penetration
LEQEMBI is penetrating the U.S. market steadily with approximately 2,000 patients currently receiving treatment and a 2.9-fold increase in patients after insurance reimbursement.
Financial Soundness
The company's financial position remains solid, with a stable equity ratio and ongoing dividend payments.
Subcutaneous Formulation Progress
Positive progress in the development of a subcutaneous formulation for LEQEMBI, with plans to submit to the FDA by March 2024.